British American Tobacco (LSE: BATS) climbs 4% to 4,552p as defensive rotation lifts UK tobacco

British American Tobacco closed up 3.95% at 4,552p on Tuesday, the second-largest gainer on the FTSE 100 and a near-touch of its 52-week high at 4,673p. The move came in the same session that saw UK domestic banks dump 3% to 4% on rising gilt yields and political risk, with capital rotating out of rate-sensitive financials and into defensive cash generators. For BATS, the combination of a 5.7% dividend yield, dollar-earning US business and reaffirmed FY26 guidance is exactly the profile institutional money buys when bond yields are pushing equity multiples lower across the rest of the index.

Why did the British American Tobacco share price rise nearly 4% on a day when most of the FTSE 100 was selling off?

There is no company-specific news on BATS today. The move is a classic defensive rotation, and it tells you what large institutional money is doing inside the UK market on May 12. With 30-year gilt yields above 5.80% and 10-year yields at 5.00%, the discount rate applied to long-duration earnings has gone up sharply. That hurts growth-tilted stocks and rate-sensitive banks. It also makes the income side of equity returns more important for total return investors, and the highest-yielding defensives on the FTSE 100 become a natural home for capital that wants to stay in equities but reduce sensitivity to UK domestic growth.

BATS fits that template. The dividend yield at current levels sits around 5.7%, comparable to a 10-year gilt but with USD revenue exposure and a buyback layered on top. The company has consistently bought back stock through 2026, including a fresh cancellation of repurchased shares announced on May 11. Layered onto that, the bond market sell-off is partly being driven by the US-Iran standoff and Brent at $105, both of which are textbook inflationary shocks. Tobacco companies have historically demonstrated meaningful pricing power through inflationary periods because per-stick price increases pass through to addicted consumers without material volume elasticity. That is the second leg of the defensive case the market is paying for today.

The third leg is geographic. BATS earns the majority of its operating profit in USD-denominated markets, most notably the United States. With sterling under pressure from gilt market stress, USD-translated earnings rise in GBP terms, which mechanically supports the share price in London. That FX translation tailwind compounds the underlying defensive bid.

What did British American Tobacco confirm in its 2026 guidance and where do the numbers sit now?

BATS reaffirmed its full-year 2026 guidance, originally set on 12 February 2026, indicating performance at the lower end of constant-currency ranges of 3% to 5% revenue growth, 4% to 6% adjusted profit from operations growth, and 5% to 8% adjusted diluted EPS growth, with both adjusted for Canada. The Canada adjustment relates to legacy provincial tobacco litigation that has been ringfenced from underlying performance.

The growth profile is built on two pillars. The combustibles business is delivering above-trend pricing in the US, where the company has executed commercial actions through 2025 and into 2026 that resulted in market share stabilisation alongside per-stick pricing growth. CEO Tadeu Marroco described the US business as having delivered strong growth driven by sustained combustibles momentum. The second pillar is the smokeless portfolio, which spans Vuse vapour products, glo heated tobacco and Velo modern oral nicotine pouches. Smokeless products generated 18.2% of group revenue in 2025 and management is targeting 50% of group revenue from these categories by 2035, with a near-term ambition of 50 million adult smokeless consumers by 2030. The current installed base is over 31 million users.

For retail investors, that guidance is doing the heavy lifting on conviction today. A reaffirmed top-line and earnings range, combined with a defensive narrative, is a powerful combination when other parts of the UK market are getting hit with discount rate compression.

How does the BAT smokeless strategy compare to Philip Morris International on next-generation products?

This is the central long-term question for BATS shareholders. Philip Morris International is the global benchmark for the heated tobacco transition through its IQOS franchise, and the market continues to assign PMI a meaningfully higher valuation multiple on the strength of that next-generation positioning. BATS has the broadest smokeless portfolio across all three reduced-risk categories (vapour, heated, modern oral), but it has not yet demonstrated PMI’s level of category dominance or pricing power in any single one.

The investment case for BATS rests on the company narrowing that gap. Vuse leads global vapour by retail share. Velo is the number one modern oral nicotine pouch outside the United States, where Philip Morris’s ZYN remains dominant. The glo heated tobacco franchise is growing but trails IQOS in market share and brand equity in Japan and Europe. BATS management has committed to reach the 50% smokeless revenue mix by 2035, which would represent a structural transition rather than incremental growth.

The risk for retail investors is execution speed. If the smokeless transition stalls and the combustibles business decelerates, BATS would become more exposed to the secular volume decline in cigarettes, which the company itself projects at around 2% globally in 2026. The reaffirmed guidance at the lower end of ranges is the market’s reminder that this transition is happening at a measured pace rather than accelerating.

What does the US menthol cigarette regulatory question mean for BATS now?

US menthol regulation has been the single largest overhang on the BATS investment case for several years. At the time the previous administration’s FDA proposed standards to ban menthol as a characterising flavour in cigarettes and cigars, around 30% of BAT’s operating profit was tied to US menthol cigarette sales. That proposal was repeatedly delayed and has not been finalised under the current administration.

The market has been gradually pricing out the menthol ban tail risk, which is one reason BATS has rerated from sub-3,000p in early 2025 to above 4,500p today. If a final ban is enacted, BATS would face a structural earnings hit alongside its US competitors. If the proposal continues to stall or is withdrawn, the rerating leg of the BATS thesis has further to run.

Retail investors should also watch the FDA’s vapour Premarket Tobacco Product Application process. The agency has previously issued Marketing Denial Orders against Vuse Alto menthol and mixed berry products, and the regulatory backdrop on flavoured vapour products remains a live risk to the smokeless growth story.

How does the BATS dividend and buyback compare to other FTSE 100 income stocks?

At 4,552p with a forward yield around 5.7%, BATS sits among the highest-yielding FTSE 100 names alongside Legal & General, Phoenix Group and HSBC. What differentiates BATS is the combination of yield with the buyback. The company has been consistently repurchasing shares through 2026 and cancelling them, which lifts EPS for the remaining holders and compounds total return alongside the cash dividend.

The company’s BAT International Finance subsidiary listed €500 million of guaranteed notes on the London Stock Exchange on 11 May 2026, which is part of the routine treasury management of the group’s debt stack and supports the funding of both shareholder returns and operational investment. Net debt has continued to come down over the past two years on the back of the disposal of the Russian and Belarusian businesses and disciplined capital allocation.

For income-focused retail investors, BATS is a yield-plus-buyback compounder. For total return investors, the question is whether the smokeless transition can drive multiple expansion from the current low-double-digit forward P/E, with the dividend yield acting as the floor.

How does the macro setup of high gilt yields, oil at $105 and US-Iran tension actually help BATS?

The macro picture today is doing three things simultaneously for the BATS share price. First, the rotation out of UK rate-sensitive financials is creating institutional inflows into UK defensives, and BATS, Imperial Brands, GSK, Haleon, Unilever and Compass Group were all in the green on Tuesday. The pattern is recognisable.

Second, the sterling weakness embedded in the gilt market sell-off is favourable for translated USD earnings. BATS reports in sterling but generates the majority of its profit in dollars, so any sustained GBP/USD weakness mechanically lifts reported numbers. The same logic applies to translated emerging market earnings, which become more valuable when investors are looking for hard-currency cash generators.

Third, the inflation impulse from $105 oil is precisely the environment in which tobacco companies have historically demonstrated their pricing power. The category has shown consistently low volume elasticity to per-stick price increases over multi-decade periods. That allows BATS to recover input cost inflation and protect operating margins, which is the opposite of what happens in retail, hospitality or discretionary spending categories that lose volume during inflationary stress.

What is the retail investor angle and what are forums saying about BATS at 4,552p?

BATS sits in a slightly different retail investor profile than the UK domestic banks or growth names. The shareholder base is dominated by income-focused private investors, dividend reinvestment plan holders and pension allocators. Forum activity on London South East and the broader UK income investor community has been positive through 2026, with the share price re-rate from sub-3,000p widely interpreted as the long-running ESG discount working its way out as institutional ESG mandates have evolved.

The debate that does exist on BATS forums centres on the smokeless transition timing and whether the current valuation already prices the next-generation product mix shift. Bulls point to the consistent guidance delivery, the buyback, and the 5.7% yield as sufficient on their own. Bears argue that combustibles will eventually accelerate their volume decline and that the smokeless margin profile remains structurally below combustibles, which will compress group operating margins over the long run.

The next major catalyst is the half-year 2026 results scheduled for 30 July, when the market will get its first read on whether smokeless growth is tracking the low-double-digit range guided in February and whether the lower-end commentary remains valid.

Key takeaways for retail investors watching British American Tobacco

• BATS rose 3.95% to 4,552p on Tuesday with no company-specific news, driven by defensive rotation as UK gilt yields spiked, banks sold off, and capital sought high-yielding cash generators with USD earnings exposure.
• The dividend yield sits around 5.7% with an active share buyback that cancels repurchased stock, creating a yield-plus-buyback total return profile competitive with 10-year gilts but with FX translation upside.
• FY26 guidance has been reaffirmed at the lower end of 3% to 5% revenue growth, 4% to 6% adjusted profit growth and 5% to 8% adjusted EPS growth, with the US combustibles business and smokeless portfolio doing the heavy lifting.
• Smokeless products (Vuse, glo, Velo) represented 18.2% of group revenue in 2025, with management targeting 50% of group revenue from these categories by 2035 and 50 million adult smokeless consumers by 2030.
• The US menthol ban remains the single largest overhang and continues to be deferred, with each delay supporting the share price rerating that has lifted BATS from sub-3,000p in early 2025 to near 4,673p today.
• The competitive gap to Philip Morris International on next-generation products is the central long-term question, with BATS broader across all three smokeless categories but lacking PMI’s category dominance in heated tobacco.
• The next major catalyst is the H1 2026 results on 30 July 2026, which will show whether smokeless growth is tracking guidance and whether sterling weakness and US momentum continue to support reported earnings.